Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03299946
Title Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC)
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Sidney Kimmel Comprehensive Cancer Center
Indications

hepatocellular carcinoma

Therapies

Cabozantinib + Nivolumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.